Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi Buys Abgent, a US-China Antibody Maker

publication date: Oct 14, 2011
WuXi PharmaTech, a leading China CRO, has acquired Abgent, Inc., a provider of antibodies and custom services based in Suzhou and San Diego. The price was not disclosed. Because Abgent is a well-established antibody manufacturer, the transaction underscores the growing importance of biologics to WuXi’s business. Dr. Ge Li, Chairman and CEO of WuXi characterized the acquisition as “small but strategically important.” More details....

Stock Symbol: (NYSE: WX)

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital